The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
More top news
American businesses have begun severing ties with controversial pro-gun group the NRA in the wake of the latest mass school shooting.
The account claimed to have been started by Daisy's uncle, raising money for funeral costs - but police say the family are not involved.
More than 400 people have died in a week of bombardment in rebel-held eastern Ghouta in Syria.